-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, after a comprehensive safety review, including two meetings of the CDC Immunization Practice Advisory Committee, the US FDA and the US Centers for Disease Control and Prevention (CDC) announced that they would cancel the recommendation to suspend the use of Johnson & Johnson's new crown vaccine in the United States and resume the vaccine.
Previously, due to the discovery of 6 rare and severe thrombosis patients in the population after the adenovirus new crown vaccine Ad26.
The two organizations came to the following conclusions after extensive and rigorous security assessments:
·Ad26.
·
· TheUS FDA and CDC have confidence in the safety and effectiveness of this vaccine to prevent COVID-19.
·
· TheFDA has determined that existing data show that the known and potential benefits of the vaccine in individuals 18 years of age and older outweigh the known and potential risks.
·
·Existing data indicate that the probability of TTS is very low, but the FDA and CDC will remain vigilant and continue to investigate the risk.
·
Vaccinated health care providers and vaccinators or caregivers should consult the latest vaccine leaflet.
"Safety is our top priority.
Reference materials:
[1] FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.
